These studies strongly suggest that tumor specific nitric oxide donors that deliver high amounts of nitric oxide and reactive species to clinical resistant tumors may be extremely useful in treating human tumors overexpressing ABC transporters, including cancer stem cells. The gene discussed is ABCG2; the disease is cancer.